Table 1.
Patient and treatment characteristics.
| n=14 | |
|---|---|
| Demographics | |
| Median age (range, years) | 60 (24-78) |
| Male sex | 12 (86%) |
| Histopathology | |
| DLBCL | 12 (86%) |
| CD5+ high grade BCL | 1 (7%) |
| Blastoid variant mantle cell | 1 (7%) |
| DLBCL cell of origin (n=12) | |
| Germinal center B-cell | 8 (67%) |
| Activated B-cell | 4 (33%) |
| Transformed FL | 4 (29%) |
| Pre-CART treatment history | |
| Median pre-CART regimens (range) | 4 (2-8) |
| Pre-CART HDT+AHCT | 4 (29%) |
| Prior radiotherapy | 5 (36%) |
| CART treatment | |
| Product | |
| JCAR017 | 7 (50%) |
| Tisagenlecleucel (tisa-cel) | 3 (21%) |
| 19-28z | 2 (14%) |
| Axicabtagene ciloleucel (axi-cel) | 1 (7%) |
| EGFRt/19-28z/4-1BBL "armored" CAR | 1 (7%) |
| Conditioning regimen | |
| Cyclophosphamide and fludarabine (Cy/Flu) | 10 (71%) |
| Z-BEAM | 1 (7%) |
| R-BEAM | 1 (7%) |
| Bendamustine | 1 (7%) |
| HiDAC + Dexamethasone + Cy/Flu | 1 (7%) |
| Best post-CART response | |
| CR | 5 (36%) |
| PR | 6 (43%) |
| PD | 3 (21%) |
| Median days to first post-CART relapse (range) | 73 (26-367) |
| SRT characteristics | |
| Median duration from CART infusion to SRT (months) | 5.3 (1.1-42.1) |
| RT given for first relapse | 10 (71%) |
| Extent of disease at SRT | |
| Localized | 6 (43%) |
| Advanced | 8 (67%) |
| sAA-IPI at SRT | |
| Low risk | 3 (21%) |
| Low-intermediate risk | 3 (21%) |
| High-intermediate risk | 4 (29%) |
| High risk | 4 (29%) |
| SRT treatment areas | |
| Extranodal | 7 (50%) |
| Nodal | 5 (36%) |
| Mixed nodal and extranodal | 2 (14%) |
| SRT treatment modality | |
| Intensity modulated radiotherapy (IMRT) | 7 (50%) |
| Conventional photon radiotherapy | 5 (36%) |
| 3D conformal radiotherapy | 2 (14%) |